Thiotepa

Generic Name
Thiotepa
Brand Names
Tepadina, Thiotepa Riemser
Drug Type
Small Molecule
Chemical Formula
C6H12N3PS
CAS Number
52-24-4
Unique Ingredient Identifier
905Z5W3GKH
Background

N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...

Indication

ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions
Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
Associated Therapies
-
Clinical Trials
Related News

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2004-08-20
Last Posted Date
2013-05-30
Lead Sponsor
Hackensack Meridian Health
Registration Number
NCT00004900
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-08-11
Last Posted Date
2012-11-09
Lead Sponsor
NYU Langone Health
Target Recruit Count
60
Registration Number
NCT00002619
Locations
🇺🇸

Kaplan Cancer Center, New York, New York, United States

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

First Posted Date
2004-08-02
Last Posted Date
2013-01-31
Lead Sponsor
University of Arizona
Target Recruit Count
30
Registration Number
NCT00003068
Locations
🇺🇸

Arizona Cancer Center, Tucson, Arizona, United States

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2004-07-16
Last Posted Date
2011-03-07
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
30
Registration Number
NCT00003877
Locations
🇺🇸

Ireland Cancer Center, Cleveland, Ohio, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
First Posted Date
2004-07-08
Last Posted Date
2011-03-24
Lead Sponsor
Georgetown University
Target Recruit Count
50
Registration Number
NCT00003297
Locations
🇺🇸

Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

First Posted Date
2004-07-01
Last Posted Date
2013-02-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
156
Registration Number
NCT00002704
Locations
🇺🇸

West Virginia University Hospitals, Morgantown, West Virginia, United States

🇺🇸

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 67 locations

Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors

First Posted Date
2004-05-25
Last Posted Date
2014-07-28
Lead Sponsor
Children's Oncology Group
Target Recruit Count
25
Registration Number
NCT00003846
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

and more 10 locations

Biological Therapy in Treating Women With Metastatic Breast Cancer

Phase 1
Conditions
Breast Cancer
First Posted Date
2004-05-24
Last Posted Date
2013-12-19
Lead Sponsor
St. Luke's Medical Center
Target Recruit Count
60
Registration Number
NCT00002780
Locations
🇺🇸

St. Luke's Medical Center, Milwaukee, Wisconsin, United States

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-21
Last Posted Date
2013-06-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
60
Registration Number
NCT00003101
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

🇺🇸

Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 4 locations

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
First Posted Date
2004-05-12
Last Posted Date
2014-12-16
Lead Sponsor
UNICANCER
Target Recruit Count
180
Registration Number
NCT00002870
Locations
🇫🇷

Centre Paul Papin, Angers, France

🇫🇷

Clinique Saint Vincent, Besancon, France

🇫🇷

C.H. Bourg En Bresse, Bourg En Bresse, France

and more 29 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy